Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-10-2013 | Original Article

PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma

Authors: Rachel L. G. M. Blom, Inge R. Steenbakkers, Guido Lammering, Roy F. A. Vliegen, Eric J. Belgers, Charlotte de Jonge, Wendy M. J. Schreurs, Marius Nap, Meindert N. Sosef

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2013

Abstract

Purpose

Neoadjuvant chemoradiotherapy is increasingly used in oesophageal cancer patients. In general, small tumours are associated with a survival benefit compared to large tumours. Little is known, however, about the relationship between initial tumour volume and response to chemoradiotherapy. Therefore, the aim of this study was to determine whether the pretherapy metabolic tumour volume (MTV) on diagnostic PET/CT in oesophageal cancer patients is correlated with response to chemoradiotherapy in the resection specimen.

Methods

A consecutive series of patients underwent diagnostic PET/CT scanning prior to chemoradiotherapy and oesophagectomy. MTVs were determined on PET/CT and an automated tumour contour was generated using specified standard uptake value thresholds. Response to chemoradiotherapy was determined in the resection specimen according to the scoring system developed by Mandard et al. Patients were divided into different groups according to response to chemoradiotherapy.

Results

Between January 2008 and May 2011 a total of 115 patients underwent an oesophagectomy. The MTV determined on diagnostic PET/CT scans was available in 79 patients. Of these 79 patients, 30 (38 %) showed no residual tumour cells at the location of the primary tumour. Three of these patients presented with residual tumour cells in the lymph nodes; 27 patients (34 %) had a complete pathological response. There was a trend towards a better response in patients with a smaller MTV (p = 0.084).

Conclusion

This study demonstrated a trend towards a correlation between response to chemoradiotherapy in oesophageal cancer patients and smaller MTVs as determined on diagnostic PET/CT prior to neoadjuvant chemoradiotherapy. However, tumour volumes overlapped between groups, indicating the need for multifactorial parameters as predictors. In addition, a complete local tumour response may be accompanied by residual disease in the regional lymph nodes.

Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347:1662–9.PubMedCrossRef

Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226–34.PubMedCrossRef

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074–84.PubMedCrossRef

Mamede M, Lima AE, Oliva MR, Nosé V, Mamon H, Gerbaudo VH. FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. Am J Clin Oncol. 2007;30:377–88.PubMedCrossRef

Roedl JB, Harisinghani MG, Colen RR, Fischman AJ, Blake MA, Mathisen DJ, et al. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. Ann Thorac Surg. 2008;86:1131–8.PubMedCrossRef

Roedl JB, Colen RR, Holalkere NS, Fischman AJ, Choi NC, Blake MA. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol. 2008;89:278–86.PubMedCrossRef

Roedl JB, Halpern EF, Colen RR, Sahani DV, Fischman AJ, Blake MA. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus. Mol Imaging Biol. 2009;11:54–60.PubMedCrossRef

van Heijl M, Omloo JM, van Berge Henegouwen MI, Hoekstra OS, Boellaard R, Bossuyt PM, et al. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer. Ann Surg. 2011;253:56–63.PubMedCrossRef

Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA, et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95:1174–9.PubMedCrossRef

10.

Westerterp M, Omloo JM, Sloof GW, Hulshof MC, Hoekstra OS, Crezee H, et al. Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. Int J Hyperthermia. 2006;22:149–60.PubMedCrossRef

11.

Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900–8.PubMedCrossRef

12.

Lagarde SM, ten Kate FJ, Reitsma JB, Busch OR, van Lanschot JJ. Prognostic factors in adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol. 2006;24:4347–55.PubMedCrossRef

13.

Moureau-Zabotto L, Farnault B, de Chaisemartin C, Esterni B, Lelong B, Viret F, et al. Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2011;80:483–91.PubMedCrossRef

14.

Sobin LH, Wittekind C. TNM classification of malignant tumours. 6th ed. New York: Wiley-Liss; 2002.

15.

Boellaard R, Oyen W. The Netherlands protocol for standardisation ad quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33.PubMedCrossRef

16.

National Electrical Manufacturers Association. NEMA Standards Publication NU-2 2001: performance measurements of positron emission tomographs. Rosslyn, VA: National Electrical Manufacturers Association; 2001.

17.

Daisne JF, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V. Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. Radiother Oncol. 2003;69:247–50.PubMedCrossRef

18.

Buijsen J, van den Bogaard J, Janssen MH, Bakers FC, Engelsman S, Öllers M, et al. FDG-PET provides the best correlation with the tumor specimen compared to MRI and CT in rectal cancer. Radiother Oncol. 2011;98:270–6.PubMedCrossRef

19.

van Baardwijk A, Bosmans G, Boersma L, Buijsen J, Wanders S, Hochstenbag M, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–8.PubMedCrossRef

20.

Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73:2680–6.PubMedCrossRef

21.

Hung JJ, Jeng WJ, Liu JS. Post-treatment endoscopic biopsy for prediction of pathologic response in patients undergoing chemoradiation therapy for esophageal cancer. Ann Surg. 2010;251:990–1.PubMedCrossRef

22.

Kim MP, Correa AM, Lee J, Rice DC, Roth JA, Mehran RJ, et al. Pathologic T0N1 esophageal cancer after neoadjuvant therapy and surgery: an orphan status. Ann Thorac Surg. 2010;90:884–90.PubMedCrossRef

23.

Swisher SG, Erasmus J, Maish M, Correa AM, Macapinlac H, Ajani JA, et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101:1776–85.PubMedCrossRef

24.

Hatt M, Visvikis D, Pradier O, Cheze-le Rest C. Baseline 18F-FDG PET image-derived parameters for therapy response prediction in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2011;38:1595–606.PubMedCrossRef

25.

Lim R, Eaton A, Lee NY, Setton J, Ohri N, Rao S, et al. 18F-FDG PET/CT metabolic tumor volume and total lesion glycolysis predict outcome in oropharyngeal squamous cell carcinoma. J Nucl Med. 2012;53:1506–13.PubMedCrossRef

26.

Moon SH, Choi JY, Lee HJ, Son YI, Baek CH, Ahn YC, et al. Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck. 2013;35:15–22.PubMedCrossRef

27.

Muralidharan V, Kwok M, Lee ST, Lau L, Scott AM, Christophi C. Prognostic ability of 18F-FDG PET/CT in the assessment of colorectal liver metastases. J Nucl Med. 2012;53:1345–51.PubMedCrossRef

Title: PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma
Authors: Rachel L. G. M. Blom
Inge R. Steenbakkers
Guido Lammering
Roy F. A. Vliegen
Eric J. Belgers
Charlotte de Jonge
Wendy M. J. Schreurs
Marius Nap
Meindert N. Sosef
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-013-2468-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

PET/CT-based metabolic tumour volume for response prediction of neoadjuvant chemoradiotherapy in oesophageal carcinoma

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2013

Transient changes in the endocannabinoid system after acute and chronic ethanol exposure and abstinence in the rat: a combined PET and microdialysis study

H. William Strauss, Giuliano Mariani, Duccio Volterrani, Steven M. Larson (eds): Nuclear Oncology: Pathophysiology and Clinical Applications

Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment

The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma

PET/MRI with a 68Ga-PSMA ligand for the detection of prostate cancer